Understanding the Break Up Big Medicine Bill

Overview

In February 2026, a bipartisan pair of senators introduced the Break Up Big Medicine Act in the U.S. Senate. The legislation proposes a federal ban on overlapping ownership in healthcare, preventing a single company from simultaneously controlling an insurer or pharmacy benefit manager ("PBM") and a medical care provider. The bill has been referred to committee and is in the early stages of the legislative process. This article provides an overview of what the bill proposes, the industry context behind it, how enforcement would work, and where the legislation stands today.

What Is the Break Up Big Medicine Bill?

The Break Up Big Medicine Bill is a prescription drug pricing reform proposal that would require healthcare corporations to separate their business lines. The Break Up Big Medicine Act creates two core ownership restrictions:

• No entity may own or operate a medical provider or management services organization ("MSO") if it also owns or operates an insurance company or a PBM.
• No entity may own or operate a prescription drug or medical device wholesaler if it also owns or operates a medical provider or MSO.

The bill defines "provider" broadly to include physician groups, pharmacies, surgery centers, urgent care facilities, post-acute care organizations, and hospitals. MSOs; entities that handle administrative functions like billing, coding, scheduling, and IT for healthcare providers,  are also covered. This is notable because many investor-backed healthcare businesses use MSO arrangements to manage clinical operations while remaining compliant with state laws that restrict corporate ownership of medical practices. Under this bill, that MSO structure would not shield an owner who also holds interests in a PBM, insurer, or wholesaler.

One open question in the bill is what exactly counts as "control." The text does not spell out whether holding a minority investment stake with board representation or veto rights would fall under the prohibition. How regulators and courts interpret that term would shape how broadly the law applies in practice.

Background: Why Vertical Integration and PBM Issues Matter

The legislation responds to a long-running trend of consolidation in U.S. healthcare. Over roughly the past two decades, a small number of large corporations have assembled operations spanning health insurance, pharmacy benefits, retail and mail-order pharmacies, physician practices, and drug distribution, all housed under one corporate umbrella. This model is commonly referred to as vertical integration.

Today, a handful of PBMs handle the vast majority of prescription drug claims in the country. Each of these PBMs is owned by a parent company that also runs a health insurance plan and other healthcare operations. A similar pattern exists in drug distribution, where a small number of wholesale firms account for nearly all pharmaceutical distribution volume nationally.

This level of consolidation has brought several PBM issues to the attention of regulators and lawmakers. Areas of concern include high market concentration in PBM services, a practice known as spread pricing (where a PBM charges a health plan more for a drug than it pays the dispensing pharmacy and keeps the difference), rebate arrangements with drug manufacturers whose savings may not fully reach patients, reimbursement structures that may favor pharmacies under the same corporate parent over independent competitors, and formulary decisions that may prioritize drugs generating higher rebates over lower-cost alternatives.

Federal regulators have been active on these questions in recent years, publishing investigative reports on PBM conduct and bringing a lawsuit against major PBMs over their role in rising costs for certain medications. That case is expected to go to trial later in 2026.

The bill's sponsors have also pointed to a decline in the number of independent pharmacies and a shift toward corporate employment among physicians as evidence that existing market structures are limiting competition.

Which Types of Companies Would Be Affected?

If enacted, the bill's ownership restrictions would require changes at several types of healthcare companies:

• Large health insurers that also own PBMs, physician networks, clinics, and claims processing platforms would need to split their payer operations from their care delivery and technology businesses.
• Pharmacy conglomerates that combine an insurance arm, a PBM, a retail pharmacy chain, and primary care clinics under one parent would face a similar choice between their payer side and their provider side.
• Insurance companies with integrated PBM and specialty pharmacy divisions would need to separate those units from any provider-side holdings.
• Major drug wholesalers that have expanded into operating medical practices or clinics would need to exit either their distribution business or their provider operations.

In each case, the affected company would have to choose one side of the line, payer/PBM or provider/care delivery, and divest the other within one year of the law's enactment.

How the Bill Would Be Enforced

The legislation establishes several enforcement channels. Federal agencies responsible for antitrust oversight and healthcare regulation would both have the authority to bring actions against companies that violate the ownership restrictions. They could also challenge future mergers or acquisitions that would recreate the types of ownership combinations the bill prohibits.

State-level enforcement is also included. Attorneys general from any state could file civil lawsuits in federal court against violating entities. In addition, the bill creates a private right of action, meaning individuals who believe they were harmed by a company's noncompliance could bring their own lawsuit and seek triple the damages they suffered, plus legal fees and other equitable relief.

Any company that fails to divest within the one-year window would face mandatory penalties, including forced sale of the conflicting assets and an obligation to surrender profits earned through the prohibited arrangement.

How This Bill Fits Into Broader Drug Pricing Reform

The Break Up Big Medicine Act did not emerge in isolation. It follows a series of related proposals and regulatory actions that have shaped recent drug pricing reform news:

An earlier bill from the same sponsors, introduced in late 2024, focused specifically on preventing PBMs from owning pharmacies. The current legislation widens that framework to cover insurers, providers, wholesalers, and MSOs.

A separate proposal introduced in 2025 addressed ownership ties between insurers and healthcare providers but did not extend to pharmacies.

Congress also included PBM-specific provisions in its most recent funding legislation, targeting particular business practices and requiring more disclosure from PBMs. Those measures regulate conduct rather than mandating corporate restructuring.

At the state level, attorneys general from across the political spectrum have called on Congress to restrict PBM ownership of pharmacies, and at least one state enacted its own law on the matter, though that statute has been paused by a court order while legal challenges proceed.

Open Questions and Key Considerations

Several aspects of the bill remain unresolved:

What qualifies as "control"?

The bill prohibits owning or "controlling" the listed entities but does not define the term precisely. Whether passive investments with limited governance rights would be covered is particularly relevant for institutional investors with diversified healthcare holdings.

Reach beyond intended targets.

Some legal commentators have noted that the bill's language could affect healthcare organizations that were not its primary focus. For example, hospital systems or physician groups that operate small, subsidiary health plans could be swept in due to how certain terms are used in the text without clear definitions.

Practicality of the one-year timeline.

The companies most directly affected by this bill are large, complex organizations. Separating their business units involves unwinding contracts, reassigning personnel, splitting shared technology systems, and navigating regulatory approvals. Some observers view the 12-month deadline as ambitious given that scale of restructuring.

The case for integration.

Companies that would be subject to the bill's requirements have argued that combining insurance, pharmacy, and provider operations under one roof enables them to coordinate care more effectively. They point to integrated data sharing, streamlined referral processes, and care management programs for patients with chronic or complex conditions as benefits that depend on connected systems.

Trade group response.

The industry trade group representing PBMs has indicated that the bill is not among Congress's near-term legislative priorities.

Where Things Stand Now

As of April 2026, the Break Up Big Medicine Bill is in committee with no hearing date announced. For the bill to become law, it would need to pass both the Senate and the House in identical form.



Whether or not this specific legislation advances, it represents a notable development in the ongoing policy conversation around prescription drug pricing reform. The bipartisan sponsorship signals that questions about healthcare ownership structures are drawing attention from both sides of the political aisle. How lawmakers, regulators, and courts ultimately address these PBM issues, whether through structural separation, conduct-based regulation, or some combination of both will shape the direction of the healthcare industry going forward.